NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.15 -0.11 (-0.98 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$11.26
Today's Range$10.70 - $11.29
52-Week Range$9.07 - $21.20
Volume1.76 million shs
Average Volume1.54 million shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$346.64 million
Book Value($1.53) per share

Profitability

Net Income$-282,370,000.00

Miscellaneous

Employees515
Market Cap$1.72 billion
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.10. The biotechnology company earned $68.73 million during the quarter, compared to the consensus estimate of $81.93 million. Ironwood Pharmaceuticals's quarterly revenue was down .6% on a year-over-year basis. During the same quarter last year, the business posted ($0.25) EPS. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $385.98 million.

What price target have analysts set for IRWD?

11 Wall Street analysts have issued 12 month price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $11.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $15.3889 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

News coverage about IRWD stock has trended somewhat negative on Monday, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
  • Mr. Thomas A. McCourt, Pres (Age 62)
  • Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
  • Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (4.30%), Geode Capital Management LLC (1.26%), Westfield Capital Management Co. LP (1.22%), Northern Trust Corp (1.13%), Goldman Sachs Group Inc. (1.10%) and New York State Common Retirement Fund (0.88%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which institutional investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, State of Wisconsin Investment Board, First Republic Investment Management Inc., Westfield Capital Management Co. LP, Trustcore Financial Services LLC, DekaBank Deutsche Girozentrale, California Public Employees Retirement System and New York State Common Retirement Fund. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Which institutional investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Northeast Financial Consultants Inc, Laurion Capital Management LP, Marshall Wace LLP, Sullivan Bruyette Speros & Blaney LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.15.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.72 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  416 (Thanks for Voting!)
Underperform Votes:  509 (Thanks for Voting!)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel